Could a bone drug stop brain calcium buildup in Fahr's disease?
NCT ID NCT05662111
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether etidronate, a drug used for bone disorders, can reduce calcium deposits in the brain and slow disease progression in Fahr's disease or syndrome. 98 adults will receive either etidronate or a placebo for 12 months. The study measures changes in thinking, memory, movement, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Etidronate (a bisphosphonate drug, similar to alendronate, used to reduce calcium buildup)
- What this could lead to
- If it works, this could point toward the first treatment to slow or stop brain calcification in Fahr's disease, potentially preserving cognitive and motor function.
- What could go wrong
- This is a small, early-phase trial (phase 2) with only 98 participants. Previous evidence comes from a small case series, so the drug may not prove effective or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAHR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University College London Hospital
NOT_YET_RECRUITINGLondon, United Kingdom
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, 3584 CX, Netherlands